Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics
Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).
Read more on News-Medical-Net